secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001493152-25-018269
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari prices $2.5M registered direct offering of ADSs and warrants at $0.80/unit
--------------------------------------------------------------------------------

- Issued 3,125,000 ADSs (each representing 2,000 ordinary shares) and Series E/F warrants to purchase up to 3,125,000 ADSs each, all at $0.80 per unit.
- Gross proceeds expected ~$2.5M; closing on or about Oct 16, 2025.
- Warrants exercisable at $0.98 per ADS upon shareholder approval; 5-year term for Series E, 30-month for Series F.
- Net proceeds for working capital, general corporate purposes, and R&D on novel ADC payload.
- Placement agent Ladenburg Thalmann receives 7.2% fee plus warrants for 125,000 ADSs at $1.00.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225018269/0001493152-25-018269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225018269/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer